Expert Interview
Discussing the potential use of CT-155, a prescription digital therapeutic (PDT) designed to treat the negative symptoms of schizophrenia from Boehringer Ingelheim and Click Therapeutics.
Ticker(s): BOEHRINGER INGELHEIM, Click TherapeuticsInstitution: RUHS
- Board certified in General Psychiatry and Addiction Medicine
- Manages 300 patients with MDD and about 50 cases of people with opioid use disorder.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
